Department of Pathophysiology, Key Laboratory of Neurological Diseases of Chinese Ministry of Education, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China.
FEBS Lett. 2012 Jul 30;586(16):2522-8. doi: 10.1016/j.febslet.2012.06.018. Epub 2012 Jun 22.
Protein phosphatase-2A (PP2A) activity is significantly suppressed in Alzheimer's disease. We have reported that glycogen synthase kinase-3β (GSK-3β) inhibits PP2A via upregulating the phosphorylation of PP2A catalytic subunit (PP2A(C)). Here we studied the effects of GSK-3β on the inhibitory demethylation of PP2A at leucine-309 (dmL309-PP2A(C)). We found that GSK-3β regulates dmL309-PP2A(C) level by regulating PME-1 and PPMT1. Knockdown of PME-1 or PPMT1 eliminated the effects of GSK-3β on PP2A(C). GSK-3 could negatively regulate PP2A regulatory subunit protein level. We conclude that GSK-3β can inhibit PP2A by increasing the inhibitory L309-demethylation involving upregulation of PME-1 and inhibition of PPMT1.
蛋白磷酸酶-2A(PP2A)活性在阿尔茨海默病中显著受到抑制。我们曾报道过糖原合成酶激酶-3β(GSK-3β)通过上调 PP2A 催化亚基(PP2A(C)) 的磷酸化来抑制 PP2A。在这里,我们研究了 GSK-3β 对 PP2A 在亮氨酸-309 处抑制性去甲基化(dmL309-PP2A(C)) 的影响。我们发现,GSK-3β 通过调节 PME-1 和 PPMT1 来调节 dmL309-PP2A(C)水平。敲低 PME-1 或 PPMT1 消除了 GSK-3β 对 PP2A(C)的影响。GSK-3 可以负调控 PP2A 调节亚基蛋白水平。我们得出结论,GSK-3β 可以通过增加涉及上调 PME-1 和抑制 PPMT1 的抑制性 L309 去甲基化来抑制 PP2A。